Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Starts
- 1 Feb 2027
- Expected to end
- 31 Jan 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Panthea Core
- Matched Placebo
- Record updated
- 18 November 2026
Who can take part
- Age
- 45 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Female individuals, assigned female sex at birth, aged 45 to 65 years
- Clinician-diagnosed hypertension, either controlled or uncontrolled
- Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries
- Willing and able to provide informed consent
Who cannot take part
- Nicotine/tobacco, probiotic, or antibiotic use within the previous six months
- Surgery within the preceding six months
- Immunosuppressive or glucocorticoid therapy
- Intermittent fasting with unwillingness or inability to complete a four-week washout period before enrollment
- Diagnosis of diabetes
- Respiratory disease other than well-controlled asthma
- Severe neurological conditions, including traumatic brain injury or stroke
- History of chemotherapy
- Autoimmune disorders
- History of organ transplantation
- Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders
- Chronic illnesses that preclude participation at the investigator's discretion
- Body mass index of 40 kg/m² or greater
- Use of hormonal contraceptives or systemic exogenous hormones
- Existing endocrine abnormalities
- Inability to speak, read, or understand English
- Inability to provide informed consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 45 and 65 years old?
Where in United States
- University of Minnesota - Children's Rehabilitation CenterMinneapolis, United StatesContact: Manda Keller-RossNot yet recruiting
About the trial
What the trial wants to find out
This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.
Read full original descriptionShow less
Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.
The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.
Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.
The 2 groups in the trial
- Panthea Core SupplementationTreatment being tested
Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.
Treatment: Panthea Core
- PlaceboPlacebo, for comparison
Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.
Treatment: Matched Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans
- Criteria questions
- Built from NCT07946705, who can take part
- Record updated
- 18 November 2026